- You are here:
- Home »
- Blog »
- colon cancer »
- Overcoming Multi-drug Resistance in Colon Cancer?
Overcoming Multi-drug Resistance in Colon Cancer?
Overcoming multi-drug resistance in colon cancer is almost wishful thinking. According to the first article linked below, MDR affects more than 90% of all colon cancer deaths.
Multidrug resistance is a problem with most, if not all, types of cancer. MDR is a problem with my blood cancer, multiple myeloma.
The video below explains how different colon cancer cells can be resistant to different chemo regimens for different reasons.
How Does Drug Resistance Affect Colorectal Cancer Treatment Options?
But what if colon cancer cells could be made to be more permeable to chemotherapy regimens? The second article below poses the idea that tumor-treating fields could do this.
I don’t blog about possible therapies very often. However, TTF to reduce or eliminate MDR is the type of cancer treatment that I can follow over the next however many years it takes to develop this technology.
Are you a colon cancer patient or survivor? Scroll down the page, post a question or comment and I will reply to you ASAP.
hang in there,
David Emerson
- Cancer Survivor
- Cancer Coach
- Director PeopleBeatingCancer
Multi drug resistance in Colorectal Cancer- approaches to overcome, advancements and future success
A significant obstacle to treating cancer is multidrug resistance (MDR), which is the capacity of cancerous cells to develop resistance to both traditional and cutting-edge chemotherapeutic treatments. Following the initial discovery that cellular pumps reliant on ATP were the root of chemotherapy resistance, more research has revealed the involvement of additional mechanisms, including increased drug metabolism, reduced drug entry, and compromised apoptotic pathways.
Numerous projects have focused on MDR, and innumerable research has been conducted to better understand MDR and develop methods to mitigate its consequences. Multidrug resistance (MDR) is a key challenge in treating cancer. 90% of cancer-related fatalities are brought on by tumor metastasis and recurrence, which is possible with MDR.
Drug resistance in cancerous cells is influenced by diverse internal and extrinsic variables, including genetic and epigenetic changes, drug efflux systems, DNA repair mechanisms, apoptosis, and autophagy.
In this review paper, we list the potential hazards associated with cancer therapy in general, primarily multidrug resistance developing a theory for colorectal cancer in particular.
We discussed the unique instance of multidrug resistance in colorectal cancer in malignancies generally and 5-fluorouracil, curcumin, and lipids as viable therapy options for the condition…
Cell Permeability Induced by Tumor Treating Fields (TTFields) as a Physical Approach to Improve Chemotherapy Uptake and Overcome Multidrug Resistance
Abstract
Results
TTFields-induced cancer cell permeability is a pan-cancer phenomenon absent in noncancerous cells
The optimal frequency for the cytotoxic effects of TTFields varies according to cancer type (19), prompting evaluation of their effects on cellular permeability across multiple cancer cell lines over a relevant frequency range.
Cellular permeability was assessed by measuring the uptake of the fluorescent exclusion dye 7-AAD, which cannot traverse intact plasma membranes of viable cells. Cells were exposed to TTFields for 24 hours, and 7-AAD was added 15 minutes prior to the end of treatment.
Maximal membrane permeability occurred at 300 kHz in mammary carcinoma (4T1), glioblastoma (U-87 MG), and Lewis lung carcinoma (LL/2) cells, whereas uterine sarcoma (MES-SA) and ovarian carcinoma (A2780) cells exhibited peak permeability at 150 kHz (Fig. 1A–E; Supplementary S1A–S1D). These frequencies differed from those inducing maximal cytotoxicity [150 kHz for 4T1 (Supplementary Fig. S1E) and LL/2 (27), 200 kHz for U-87 MG (19) and A2780 (28), and 100 kHz for MES-SA cells (Supplementary Fig. S1F)].
Notably, noncancerous cells (lung fibroblasts, MRC-5; brain endothelial cells, HBMVEC) showed no increased permeability following TTFields exposure (Fig. 1F and G)…
In conclusion, our findings highlight important implications for incorporating TTFields into clinical strategies aiming to enhance the effectiveness of standard chemotherapeutics, particularly in cancers exhibiting MDR phenotypes. Future studies could explore exploiting TTFields-induced cancer cell permeability for use with small-molecule targeted therapies, such as PARP inhibitors…”
Overcoming multi-drug resistance in colon cancer Overcoming multi-drug resistance in colon cancer